From the Blood Journals

From the Blood Journals

Research from the Blood family of journals: Blood and Blood Advances

HLA-Haploidentical Relative and Matched Unrelated Donor Transplant Lead to Similar Survival Outcomes in MDS

Transplantation with an HLA-haploidentical relative donor is associated with similar two-year survival rates compared with transplantation with a matched unrelated donor in patients with...

Ixazomib Combination Improves PFS Versus Placebo in Patients With Transplant-Ineligible Myeloma

When researchers added ixazomib to continuous lenalidomide-dexamethasone (Rd) in patients with newly diagnosed, transplant-ineligible multiple myeloma (MM), they observed that the treatment regimen was...

Transplant Improves Health-Related Quality of Life for Patients With SCD and Transfusion-Dependent Thalassemia

Hematopoietic cell transplantation (HCT) is associated with significant improvements in health-related quality of life (HRQoL) in patients with sickle cell disease (SCD) and transfusion-dependent...

International Working Group Publishes Revised Definitions for Remission, Relapse in Immune TTP

The International Working Group (IWG) for thrombotic thrombocytopenic purpura (TTP) has published revised definitions for response, exacerbation, remission, and relapse of immune-mediated TTP (iTTP)...

Older Age, Pre-Existing Comorbidities Increase Poor Outcomes in Patients With SCD and COVID-19

Patients with sickle cell disease (SCD) have poor outcomes associated with COVID-19, particularly if they are older or present with end organ damage, acute...

Risk of Subsequent Malignant Neoplasms Is Low in Children With Hodgkin Lymphoma

A study published in Blood suggests that children and adolescents with intermediate-risk Hodgkin lymphoma have a relatively low cumulative risk of developing subsequent malignant...

Adults With Hematologic Malignancies and COVID-19 Fare Worse Than Children

Adults with hematologic malignancies and COVID-19 infection have a substantially higher risk of death compared with children with hematologic malignancies and COVID-19, according to...

Avelumab Shows Clinical Activity in Relapsed/Refractory Extranodal Natural Killer/T-Cell Lymphoma

Avelumab is clinically active in patients with relapsed or refractory extranodal natural killer/T-cell lymphoma (ENKTL), although researchers observed a lower-than-expected response rate, according to...

Leukemia Antigen–Specific Donor-Derived T Cells Enhance Graft-Versus-Leukemia Effects in Post-Transplant AML/MDS

For patients with acute myeloid leukemia (AML) or myelodysplastic syndromes (MDS) whose disease relapses following a hematopoietic cell transplantation (HCT), unselected donor lymphocytes typically...

Researchers Develop a Validated Pediatric Disease Risk Index for AML and ALL

A pediatric disease risk index (DRI) reported in Blood was capable of stratifying children with acute myeloid leukemia (AML) and acute lymphocytic leukemia (ALL)...

Current Issue

April 2021 Volume 7 Issue 5

This issue examines long-haul COVID-19, central nervous system relapse in non-Hodgkin lymphoma, and more.

Block title